Researchers at the German Center for Neurodegenerative Diseases (DZNE) and the Institute for Stroke and Dementia Research (ISD) at the LMU Medical Center have found that a protein named TREM2 may have a mitigating effect on the course of Alzheimer’s disease. In a new study led by Professor Christian Haass (LMU, DZNE) and Professor Michael Ewers (ISD, LMU), patients who have higher levels of TREM2 in their cerebrospinal fluid (CSF) at various stages of the disease have a better prognosis than those in whom the protein is present in lower amounts. This observation provides a starting point for the development of new therapeutic strategies. The study appears in the latest issue of the journal Science Translational Medicine.
…
